Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase

• Published in: Biological psychiatry (1969) Vol. 73; no. 3; pp. 219 - 224
• Main Authors: Kosten, Thomas R., Wu, Guiying, Huang, Wen, Harding, Mark J., Hamon, Sara C., Lappalainen, Jaakko, Nielsen, David A.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.02.2013; Elsevier
• Subjects: Addictive behaviors; Adult; Adult and adolescent clinical studies; Biological and medical sciences; Cocaine; Cocaine-Related Disorders - complications; Cocaine-Related Disorders - drug therapy; Cocaine-Related Disorders - genetics; dependence; disulfiram; Disulfiram - therapeutic use; Dopamine beta-Hydroxylase - genetics; Drug addiction; Drug Therapy, Combination; Female; genes; Genotype; Humans; Male; Medical sciences; Methadone - therapeutic use; Middle Aged; Opioid-Related Disorders - complications; Opioid-Related Disorders - drug therapy; Opioid-Related Disorders - genetics; polymorphism; Polymorphism, Single Nucleotide; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; treatment; Treatment Outcome; treatment; dependence; Cocaine; disulfiram; polymorphism; genes; Dopamine β-monooxygenase; Drug addiction; Pharmacogenetics; Antialcohol drug; Enzyme; Genetic determinism; Ester; Treatment; Gene; Dependence; Disulfiram; Genetics; Drug of abuse; Oxidoreductases; Polymorphism

Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possible mechanisms of efficacy is through copper chelation and inhibition of an enzyme involved in catecholamine metabolism, dopamine β-hydroxylase (DβH), which converts dopamine to norepinephrine. A variant in the g...